Tivozanib and Nivolumab for advanced kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs (tivozanib and nivolumab) for people with advanced kidney cancer that is not clear cell type. It aims to see if this drug pair can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced kidney cancer that is not clear cell type (like papillary or chromophobe).
- You can have had up to one prior treatment for your cancer, including immunotherapy or targeted therapy.
- You must be 18 years or older.
- You must be well enough to be up and about (ECOG score 0-2).
- Your kidney, liver, and blood cell counts must be in an acceptable range.
- You cannot have had tivozanib or nivolumab before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs together—vorolanib (a pill that targets blood vessels in tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer)—for people with advanced kidney cancer whose prior immunotherapy combination stopped working.
This trial tests a combination of two drugs, Vorolanib and Cadonilimab, for people with advanced or metastatic clear cell kidney cancer who have not had prior treatment. It aims to see if the combination shrinks the cancer and how safe it is.
This trial tests a combination of two drugs, RP2 (an oncolytic virus injected into tumors) and tivozanib (a daily pill), for people with advanced kidney cancer that has clear-cell or sarcomatoid features and has grown after prior immunotherapy and a targeted therapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
This trial compares two immunotherapy combinations—nivolumab/relatlimab/ipilimumab vs. nivolumab/ipilimumab—as first treatment for advanced kidney cancer with clear cell features. It aims to see which combo works better for people who haven't had prior therapy.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.